Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2023-03-28 Director's Dealing
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2023-03-28 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-28 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details a stock option repricing approved by the Board of Directors, affecting executive officers' stock options. This is an announcement related to changes in management compensation and equity incentives, but it is not a full annual or quarterly report, nor is it a proxy or voting result. It is not a certification or legal proceeding. The key event is a board-approved stock option repricing, which fits best under a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit other specific categories like Remuneration Information or Share Issue/Capital Change exactly. The document length is 4607 characters, which is relatively short and typical for an 8-K filing. Therefore, the best classification is Regulatory Filings (RNS).
2023-03-28 English
S-8
Regulatory Filings
2023-03-22 English
10-K
Annual Report FY 2022
2023-03-22 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text includes an Item 2.02 announcing the issuance of a press release with financial results for the full year ended December 31, 2022, but the actual financial results are in the press release (Exhibit 99.1), not in this document. It also includes Item 5.02 announcing a promotion of a senior officer. The document itself is a regulatory filing reporting these events, not the full financial report or the press release itself. The length is about 4,831 characters, which is relatively short and consistent with a Form 8-K. Therefore, this document is best classified as a Regulatory Filing (RNS) because it reports events and references a press release but does not contain the full financial data or detailed report itself.
2023-03-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.